A national education program for pharmacists funded by the Australian Government under the Quality Use of Diagnostics, Therapeutics and Pathology program.[/caption]
While the evidence bases for both CMs and Schedule 3 sleep aids are unlikely to immediately change, a core practice consideration is the risk-benefit profile of the respective non-prescription sleep aids for the individual patient. 
Is it really insomnia?
Knowledge to practice 
Informing pharmacy practice with valuable research
PSA’s Pharmacists in 2023 vision advocates the implementation of a ‘research culture’ in Australia. Here’s how members can pursue valuable research in their own...
7CPA: An historic step forward
Last month, I was pleased to be the first PSA President to co-sign a Community Pharmacy Agreement (CPA) on behalf of the profession.
From the President: on the record
PSA is redoubling our efforts to ensure fair remuneration for pharmacists that reflects our training and expertise.
The launch of Pharmacists in 2023 in...
From the President: Valuing our most vulnerable
Pharmacists spending more time on the ground in aged care has become an urgent priority.
It is often said that a measure of civilisation...
Bumetanide for Alzheimer’s disease
Alzheimer’s disease is the most common form of dementia, affecting up to 70% of all people with dementia.1 In the early stages, symptoms can...
I take Kakadu plum, is that ok?
How the new PSA guideline can help answer this question.
When asked about bush medicine most pharmacists would struggle. Bush medicine is a form of...
